Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates For AZN, GSK, MRK, RHHBY
Zacks Investment Research | Oct 03, 2019 11:11PM ET
This week, J&J (NYSE:JNJ) settled with two counties of Ohio for $10 million related to the upcoming multidistrict litigation for opioid-based drug abuse. The FDA issued a complete response letter to AstraZeneca’s (NYSE:AZN) triple-combo inhaler, PT010 while granting approval to Roche’s (OTC:RHHBY) Rituxan to treat pediatric patients two years and older with two rare blood vessel disorders. Meanwhile, almost all pharma bigwigs presented data from cancer studies at the European Society of Medical Oncology (ESMO) congress in Barcelona, Spain.
Recap of the Week’s Most Important Stories
JNJ Settles With Ohio Counties in Multidistrict Opioid Trial: J&J announced that it has entered into a settlement with two Large Cap Pharmaceuticals Industry 5YR % Return
Here is how the seven major stocks performed in the last five trading sessions.
Last week, only J&J was in the green, rising 1.8%. AstraZeneca declined the most (5%).
In the past six months, Bristol-Myers has been the biggest gainer (6.2%) while Pfizer lost the most (17.6%).
(See the last pharma stock roundup here: Zacks Investment Research
Get The News You Want